People on the Move
Taiho Oncology
Taiho Oncology has appointed a Senior VP and Chief Commercial Officer as part of its transition “to a more fully integrated clinical development and commercial entity as it prepares for the potential marketing approval of its lead compound, TAS-102.”
Tim Whitten will lead commercialisation of the cancer drug for Taiho Oncology, a division of the Japanese company Taiho Pharmaceutical, Ltd. TAS-102 is an oral combination oncology therapy, with the nonproprietary names trifluridine and tipiracil hydrochloride. The company announced earlier this month the compound had met its endpoint of greater survival in a Phase III trial among refractory metastatic colorectal cancer (mCRC) patients.
Before joining Taiho Oncology, Whitten worked for 17 years at Bristol-Myers Squibb, in roles including VP of Marketing for US Oncology and Immunology, and VP of Global Marketing for Oncology, Immunology, and Pulmonary Diseases. He has also held senior roles at Pharmacyclics, and Transave/Insmed, where he was President and CEO.
(Picture credit: Flickr/Nicholas Raymond)
